MedTrace Logo

Leveraging EEG for Antidepressant Prediction With Duloxetine and Bupropion

NCT04388189 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2020-10-19

No results posted yet for this study

Summary

The LEAP-DB study will be conducted to validate the utility of EEG biomarkers as an aid to antidepressant treatment selection in adults with MDD.

Conditions

Interventions

DRUG

Duloxetine

FDA approved antidepressant

DRUG

Bupropion

FDA approved antidepressant

Sponsors & Collaborators

  • Alto Neuroscience

    lead INDUSTRY

Principal Investigators

  • Corey Keller, MD, PhD · Alto Neuroscience

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
22 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-15
Primary Completion
2023-05-30
Completion
2023-05-30

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04388189 on ClinicalTrials.gov